secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2022-05-18T23:59:59+00:00
Accession:  0001193125-22-153616
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO reports preclinical Pompe gene therapy data; >99% glycogen reduction in heart; trial start 2023
--------------------------------------------------------------------------------

- Median GAA enzyme activity in bone marrow reached 300-534 nmol/h/mg (p<0.005) vs 4-6 in normal mice eight months post-infusion.
- >99% glycogen reduction in heart with reversal of cardiac hypertrophy; >97% reduction in diaphragm, >85% in quadriceps.
- >95% glycogen reduction in brain and >99% in spinal cord; improved locomotor function and blood-brain barrier crossing.
- Stable engraftment at eight months with median vector copy numbers 1.9-3.6 per diploid genome; no clonal dominance observed.
- AVROBIO plans to engage regulators in 2022 and initiate a clinical trial for AVR-RD-03 in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312522153616/0001193125-22-153616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312522153616/d322523d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-153616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer